Education
About Us
Working with TipRanks
Follow Us
Insmed (INSM)
NASDAQ:INSM
INSM Analyst Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
INSM Stock 12 Month Forecast
Average Price Target
$147.38
▲(14.85% Upside)
| Highest Price Target$240.00 | Average Price Target$147.38 | Lowest Price Target$110.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Evercore ISI
$90→$110
Buy
-14.28%
Downside
Reiterated
08/22/25
Mizuho Securities
$165
Buy
28.58%
Upside
Reiterated
08/21/25
TR | OpenAI - 4o
$121→$135
Hold
5.21%
Upside
Reiterated
08/20/25
Morgan Stanley
$126→$144
Hold
12.22%
Upside
Assigned
08/20/25
J.P. Morgan
$111→$135
Buy
5.21%
Upside
Reiterated
08/19/25
William Blair
―
Buy
―
Initiated
08/19/25
Insmed's Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion OpportunitiesWe are initiating coverage of Outperform rating, based on our belief that clinical and commercial execution with Brinsupri, Arikayce, and TPIP have the potential to significantly increase Insmed’s valuation. While acknowledging that shares of Insmed are up over 450% (versus a 2% increase for the XBI) since the positive Phase III results with Brinsupri in bronchiectasis, we believe the potential for a strong commercial launch of Brinsupri in the multi-blockbuster bronchiectasis indication will keep Insmed as a “must-own” name for investors. Furthermore, there are near-term readouts that could drive market expansion across Brinsupri, Arikayce, and TPIP into additional indications, further increasing peak sales for Insmed, which we estimate at nearly $15 billion in 2035.
TR | OpenAI - 4o
$118→$121
Hold
-5.70%
Downside
Reiterated
08/14/25
Wolfe Research
$109→$173
Buy
34.82%
Upside
Reiterated
08/14/25
Stifel Nicolaus
$121→$145
Buy
13.00%
Upside
Reiterated
08/14/25
Truist Financial
$126→$139
Buy
8.32%
Upside
Reiterated
08/14/25
H.C. Wainwright
$120→$240
Buy
87.03%
Upside
Reiterated
08/13/25
TD Cowen
$135→$154
Buy
20.01%
Upside
Reiterated
08/13/25
Leerink Partners
$125→$133
Buy
3.65%
Upside
Reiterated
08/13/25
Bank of America Securities
$121→$142
Buy
10.66%
Upside
Reiterated
08/13/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
$90→$110
Buy
-14.28%
Downside
Reiterated
08/22/25
Mizuho Securities
$165
Buy
28.58%
Upside
Reiterated
08/21/25
TR | OpenAI - 4o
$121→$135
Hold
5.21%
Upside
Reiterated
08/20/25
Morgan Stanley
$126→$144
Hold
12.22%
Upside
Assigned
08/20/25
J.P. Morgan
$111→$135
Buy
5.21%
Upside
Reiterated
08/19/25
William Blair
―
Buy
―
Initiated
08/19/25
Insmed's Growth Potential: Buy Rating Backed by Strong Clinical Execution and Market Expansion OpportunitiesWe are initiating coverage of Outperform rating, based on our belief that clinical and commercial execution with Brinsupri, Arikayce, and TPIP have the potential to significantly increase Insmed’s valuation. While acknowledging that shares of Insmed are up over 450% (versus a 2% increase for the XBI) since the positive Phase III results with Brinsupri in bronchiectasis, we believe the potential for a strong commercial launch of Brinsupri in the multi-blockbuster bronchiectasis indication will keep Insmed as a “must-own” name for investors. Furthermore, there are near-term readouts that could drive market expansion across Brinsupri, Arikayce, and TPIP into additional indications, further increasing peak sales for Insmed, which we estimate at nearly $15 billion in 2035.
TR | OpenAI - 4o
$118→$121
Hold
-5.70%
Downside
Reiterated
08/14/25
Wolfe Research
$109→$173
Buy
34.82%
Upside
Reiterated
08/14/25
Stifel Nicolaus
$121→$145
Buy
13.00%
Upside
Reiterated
08/14/25
Truist Financial
$126→$139
Buy
8.32%
Upside
Reiterated
08/14/25
H.C. Wainwright
$120→$240
Buy
87.03%
Upside
Reiterated
08/13/25
TD Cowen
$135→$154
Buy
20.01%
Upside
Reiterated
08/13/25
Leerink Partners
$125→$133
Buy
3.65%
Upside
Reiterated
08/13/25
Bank of America Securities
$121→$142
Buy
10.66%
Upside
Reiterated
08/13/25
Best Analysts Covering Insmed
1 Month
xxx
Success Rate
14/22 ratings generated profit
Average Return
+13.63%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +13.63% per trade.
3 Months
xxx
Success Rate
19/23 ratings generated profit
Average Return
+35.20%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 82.61% of your transactions generating a profit, with an average return of +35.20% per trade.
1 Year
Success Rate
15/15 ratings generated profit
Average Return
+103.58%
reiterated a buy rating 15 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +103.58% per trade.
2 Years
xxx
Success Rate
23/23 ratings generated profit
Average Return
+208.05%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +208.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
INSM Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
1
6
6
5
1
Buy
42
32
36
34
49
Hold
6
6
10
7
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
49
44
52
46
62
Each month's total comprises the sum of three months' worth of ratings.
INSM Financial Forecast
INSM Stock Forecast FAQ
What is INSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 147.38.
What is INSM’s upside potential, based on the analysts’ average price target?
Insmed has 14.85% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is INSM a Buy, Sell or Hold?
Insmed has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
What is Insmed’s price target?
The average price target for Insmed is 147.38. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $240.00 ,the lowest forecast is $110.00. The average price target represents 14.85% Increase from the current price of $128.32.
The highest analyst price target is $240.00 ,the lowest forecast is $110.00. The average price target represents 14.85% Increase from the current price of $128.32.
What do analysts say about Insmed?
Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of INSM?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.